Trova il tuo studio
FILTRI
ETÀ
anni
Smouldering
Diagnosi
Ricaduto
LENALIDOMIDE
Anti-CD38
Quelli che seguono sono gli studi che soddisfano i criteri di selezione individuati a partire dalle risposte date alle domande precedenti. Ti ricordiamo tuttavia che il parere definitivo sarà il centro sperimentale a fornirlo, solo a seguito di una visita completa.
Study Comparing Two Standard Treatment In Autologus stem cell transplantation inelegible population affected by Multiple Myeloma
NCT03829371
Visualizza centri
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623
Visualizza centri
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
NCT04643002
Visualizza centri
A Study of Combination of Selinexor Pomalidomide and Dexamethasone ( SPd) versus Elotuzumab, Pomalidomide and Dexametasone (EloPD) in Subject with Previously Treated Multiple Myeloma
NCT05028348
Visualizza centri
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants with Relapsed or Refractory Multiple Myeloma (DREMM14)
NCT05064358
Visualizza centri
A Study of Teclistamab in Combination With Lenalidomide Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)
NCT05243797
Visualizza centri
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)
NCT05317416
Visualizza centri
A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)
NCT05519085
Visualizza centri